The text starts here.

News Release

April 11, 2005

Eisai and Abbott Signed a Joint Development Agreement for new indication, psoriasis, of anti-rheumatic agent D2E7 (adalimumab)

Eisai Co., Ltd.
Abbott Japan Co., Ltd.

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Abbott Japan Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Zahir Lavji) announced that Eisai and Abbott GmbH & Co., KG (Headquarters: Ludwigshafen, Germany, Managing Director: Rodolfo Viana) signed a supplemental agreement for the joint development of the new indication, psoriasis, of the anti-rheumatic agent D2E7 (Generic Name: adalimumab, fully human anti-TNF-alpha monoclonal antibody) in Japan. This agreement supplements the basic agreement signed in June 1999 for the joint development and marketing of D2E7 for rheumatoid arthritis indication in Japan.

As a result of the supplemental agreement, Eisai and Abbott Japan will jointly proceed with the clinical development in Japan for rheumatoid arthritis, Crohn's disease and psoriasis indications for D2E7. After receiving marketing authorization approval, Eisai and Abbott Japan will commercialize D2E7 in Japan.

D2E7 is an antibody medication discovered and developed by Knoll AG, a company that Abbott acquired in 2001. In the U.S. and Europe, Abbott currently markets D2E7 under the brand name of HUMIRA(R) as an anti-rheumatic agent. Abbott retains the sole right to develop D2E7 on its own for Crohn's disease and psoriasis indications in the U.S. and Europe.

Crohn's disease and psoriasis are refractory diseases, and effective medicines are sought-after in Japan. Eisai and Abbott believe that the development of D2E7 will contribute to the benefit of patients suffering from these diseases.

[Glossary is attached for reference]

Eisai Co., Ltd. Abbott Japan Co., Ltd.
Corporate Communications Department Communication Department
Tel: 81-3-3817-5120Tel: 81-3-3225-1174

<Note to the editor>

•  What is Crohn's disease?
Crohn's disease is a serious chronic and inflammatory disease of the gastrointestinal tract and is typically diagnosed before age 30. The disease may cause elongated or irregular-shaped ulcers, swelling in the lining or narrowing of the inner surface of the bowels. Common symptoms of the disease include diarrhea, cramping, abdominal pain, weight loss, fever and in some cases rectal bleeding.

•  What is psoriasis?
Psoriasis is a chronic, non-contagious autoimmune skin disease characterized by very dry, scaly and cracked skin; skin pain; and patches of red, raised skin known as "plaques." It develops on head, sides of limb that can be stretched, or lumber. Itching is often observed in the half of psoriasis patients. The peak age to diagnose psoriasis is 20s and 50s for female, 50s for male.

•  TNF-alpha
TNF (Tumor Necrosis Factor) is a cytokine that mediate interaction between the cells that are found to be vulnerary to tumor cells. TNF-alpha is produced by various cells such as macrophage, lymphocytes, vascular endothelial cells, and enhances inflammatory reaction or activates inflammatory cells.

•  Monoclonal antibody
Monoclonal antibody is derived from cells that produce antibodies. It has even structure of e.g. amino-acid sequence.